Company News-宜明昂科英文

Company News

Company News

Company News

ImmuneOnco Listed on the Main Board of the HKEX

(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).

ImmuneOnco Biopharmaceuticals Named to KPMG China's "2nd Annual Biotechnology Innovation Top 50 Companies List"

On April 7, 2023, KPMG China's "2nd Biotechnology Innovation Top 50" award ceremony was held simultaneously in Beijing, Shanghai and Shenzhen, and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was

ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China

On March 24, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the patent applications for their independently developed products, IMM47 (CD2

ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the phase I clinical trial of IMM2520, a bispecific antibody-receptor fusion protein that targets

ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting

On March 21, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the company will present the preclinical research data of IMM47 (CD24 antibody

ImmuneOnco Biopharmaceuticals officially launches phase IIa clinical trial targeting late-stage follicular lymphoma (FL) with IMM0306

On March 17, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that its self-developed bispecific antibody-receptor recombinant protein drug targe

总计 63 1 2 3 456 7 8 9 10 11